COMMUNIQUÉS West-GlobeNewswire

Revive Therapeutics Ltd. Announces Offering of Up to $3 Million
24/01/2024
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS [...]
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24/01/2024
STAMFORD, Conn., Jan. 24, 2024 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of January 23, 2024, the compensation [...]
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
24/01/2024
Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral [...]
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
24/01/2024
Daix (France), Long Island City (New York, Etats Unis), le 24 janvier 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites [...]
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24/01/2024
FARMINGTON HILLS, Mich., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies [...]
Tourmaline Bio Announces Proposed Public Offering of Common Stock
24/01/2024
NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of [...]
23andMe to Report FY2024 Third Quarter Financial Results
24/01/2024
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and [...]
ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo
24/01/2024
SOLANA BEACH, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine [...]
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024
24/01/2024
Year-over-year revenue grows 12% , operating profit down 2% , non-GAAP operating profit up 20% Resumed share repurchase program, repurchased $50 million during quarter Note: A webcast of ResMed’s conference call will be [...]
UPDATE -- Visory Health Announces The Kroger Company As Preferred Pharmacy
24/01/2024
The prescription discount card has helped customers save over $5 billion on prescriptions at over 35,000 pharmacies nationwide ORLANDO, Fla., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Visory Health , a women-led, patient-first [...]
Transparency Notifications from Shareholders
24/01/2024
PRESS RELEASE REGULATED INFORMATION 24 January 2024, 06:00 pm CET Ghent, Belgium – 24 January 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of [...]
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
24/01/2024
Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM) TARRYTOWN, N.Y. and WASHINGTON, D.C., Jan. 24, 2024 (GLOBE NEWSWIRE) -- [...]
CORRECTION -- Sirona Biochem Corporate Update January 2024
24/01/2024
VANCOUVER, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF), please note that in the 8th [...]
OrphAI Therapeutics Announces Appointment of Jay Fine to Board of Directors
24/01/2024
Seasoned leader in drug discovery and development GUILFORD, Conn., Jan. 24, 2024 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc. (“OrphAI”) , a clinical-stage biopharmaceutical company developing novel therapeutics for [...]
Rejuvant Emerges as No. 1 Longevity Solution in TruMe Labs DNA Methylation Test Results
24/01/2024
FERNANDINA BEACH, Fla., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Ponce de Leon Health, the creators of Rejuvant , revealed vital insights for longevity enthusiasts in a LinkedIn post published by its founder and CEO, Tom [...]
500th Use of the Galaxy System™ in the United States Conducted at CHI Memorial in Tennessee
24/01/2024
The procedure marks an important achievement as the Noah Galaxy System’s imaging-integrated robot-assisted bronchoscopy solution continues to roll out to health systems and physicians across the U.S. SAN CARLOS, Calif [...]
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
24/01/2024
New ticker symbol goes into effect immediately VANCOUVER, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology [...]
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
24/01/2024
-Project NextGen Collaboration will Support Capricor’s StealthX™ Exosome Platform and Provide Non-Dilutive Support for Advancement into the Clinic- SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics ( [...]
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
24/01/2024
Subject enrollment is expected in Q1 2024 OCALA, Fla., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has received authorization from the [...]

Pages